A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant is a research paper published in PLoS ONE (2021). On theSindex it has a DataRank of 0. It has been cited 5 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NHLBI NIH
Grant: K08HL143189
MSKCC Cancer Center
Grant: NCI P30 CA008748
NHLBI NIH HHS
Grant: R01 HL123340
NCI NIH HHS
Grant: R01 CA228308
NCI NIH HHS
Grant: P30 CA008748
NCI NIH HHS
Grant: P01 CA023766
National Institutes of Health
Grant: 2P30CA008748-43
MOUSE GENETICS
National Institutes of Health
Grant: 5K08HL143189-03
Microbiota mechanisms and biomarkers in GVHD
Novartis
Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center
FWCI
0.53
Citation Percentile
0.6%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals